Trials

MRD trials

The curated index is a sourced list of studies. Accruing is the live ClinicalTrials.gov recruiting set. DYNAMIC-III is not in the curated index because it is registered in Australia and New Zealand, not with an NCT id.

Curated Accruing

NCT03830866Phase 3CompletedGynecologic

Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA)

Completed phase 3 CALLA trial (770 actual enrollment) of durvalumab plus chemoradiotherapy versus chemoradiotherapy alone in locally advanced cervical cancer. Primary clinical result: Monk et al., Lancet Oncol 2023 (PMID 38039991), negative for investigator-assessed PFS in a biomarker-unselected ITT population (HR 0.84, 95% CI 0.65–1.08, P=0.17). ctDNA analysis is correlative, not a treatment-assignment biomarker. ClinicalTrials.gov API v2 on 13 Nov 2026: COMPLETED, start 2019-02-15, primary completion 2022-01-20, completion 2023-07-03, last update 2024-07-26, lead sponsor AstraZeneca.

AstraZeneca

NCT05212779Not reportedUnknownGynecologic

Predicting the Risk of Ovarian Cancer Recurrence Using Circulating Tumor DNA to Assess Residual Disease

Observational study of ctDNA to predict ovarian-cancer recurrence by assessing residual disease (estimated n=45). ClinicalTrials.gov API v2 on 13 Nov 2026: status UNKNOWN, start 2022-10-07, primary completion 2024-12-30, last update 2024-02-01. No peer-reviewed primary results paper was identified in this review.

Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)

NCT05872724Phase 2RecruitingGynecologic

Postoperative adjuvant therapy for cervical cancer based on minimal residual disease

Phase 2 trial that assigns adjuvant treatment from risk group and MRD status. The registry primary outcome is 3-year disease-free survival. ClinicalTrials.gov lists the study as recruiting.

Suzhou Municipal Hospital

NCT06071286Not applicableRecruitingGynecologic

Sequential ctDNA profiling in advanced ovarian cancer

Interventional study of serial circulating tumor DNA in suspected advanced ovarian cancer. The registry lists the phase as not applicable and the primary outcome as the ability of ctDNA to detect recurrence. ClinicalTrials.gov lists the study as recruiting.

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

NCT07339384Phase Not applicableNot yet recruitingGynecologic

Signatera Assessment in Early-Stage Endometrial Cancer

Not-yet-recruiting interventional trial SIGNAL-EMC 101 (Natera sponsor): after surgery, high-intermediate-risk stage I endometrial-cancer patients are stratified by postoperative Signatera Genome ctDNA; ctDNA-negative patients are randomized 1:1 to ctDNA-guided observation versus adjuvant vaginal brachytherapy, with a 3-year RFS non-inferiority primary endpoint. Planned enrollment 1,010. ClinicalTrials.gov API v2 on 13 Nov 2026: NOT_YET_RECRUITING, start October 2026, primary completion October 2034, last update 2026-06-17, phase N/A.

Natera, Inc.